Elucid Raises $55M—One Heart-AI Product Still Awaits FDA Review

Elucid’s September 2 financing notice put its oversubscribed Series D at $55 million and total funding to date at approximately $185 million. The Boston medical-technology company identified IAG Capital Partners and Elevage Medical Technologies as participants and disclosed a new, unnamed large medtech investor.

The financing does not give every component of Elucid’s planned cardiovascular imaging platform the same regulatory status. Independent coverage from MobiHealthNews confirms that Plaque-IQ is FDA-cleared, while the separate BioIntegrated FFR-CT technology was still moving through the FDA process when the round was disclosed.

What the Series D establishes—and what it does not

The round provides new capital for commercialization, product development and clinical research. It does not establish a valuation, product revenue, market share or the number of hospitals and imaging centers using Elucid’s software; none of those figures accompanied the financing disclosure.

The description of the round as oversubscribed indicates that investor demand exceeded the amount Elucid chose to accept, but it is not a measure of clinical adoption. The cumulative funding figure is similarly a financing metric, not evidence that the platform improves outcomes or has become routine in cardiovascular care.

Regulatory status: two products at different gates

Elucid plans to combine plaque composition, vessel anatomy and physiological assessment in a broader clinical workflow. At the financing date, however, its two named products occupied distinct regulatory positions:

• Plaque-IQ — FDA-cleared: The software processes previously acquired CT angiography images to support plaque quantification and morphology assessment. The FDA database entry for K241524 records a September 12, 2024 decision that found Elucid PlaqueIQ substantially equivalent through the traditional 510(k) pathway.
• BioIntegrated FFR-CT — under FDA review: This separate product is intended to estimate how coronary artery disease affects blood flow without an invasive pressure-wire procedure. A September 2 evidence review found that its 510(k) submission remained under review and identified no later clearance or completed pivotal result.

A 510(k) clearance is not premarket approval. More importantly for this financing story, Plaque-IQ’s clearance applies only to that device and its stated intended use; it cannot be extended to BioIntegrated FFR-CT because Elucid plans to place both products in one reporting workflow.

Elucid describes Plaque-IQ as using plaque analysis validated against histopathology and presents BioIntegrated FFR-CT as a way to integrate anatomy, plaque biology and physiology. Those are company product and performance claims. They are separate from the narrower regulatory fact that one product is cleared and the other was still awaiting an FDA determination.

How the $55 million is intended to be used

The disclosed uses of the proceeds fall into four areas: commercial expansion of the clinical platform, deeper partnerships with medical-technology companies, continued AI research and development, and clinical studies. The capital is also expected to support work toward a broader commercial launch if BioIntegrated FFR-CT obtains clearance.

Each area carries a different execution test. Commercial spending can support sales, integrations and deployment of Plaque-IQ; regulatory spending can advance the pending submission; and research funding can produce technical or clinical evidence. Progress in one category does not demonstrate success in the others.

The round therefore finances both an existing commercial opportunity and a prospective product strategy. Plaque-IQ may be marketed within its cleared intended use, but the new money does not turn the FFR-CT component into a cleared product or establish when an FDA decision will arrive.

Clinical evidence and commercial adoption remain separate milestones

Regulatory clearance gives a manufacturer a basis to market a device for its stated use. It does not by itself prove improved patient outcomes, broad physician acceptance, successful integration into radiology and cardiology workflows, or favorable economics for health systems.

Elucid is developing additional evidence through AI-PREDICT. The company’s July 9 AI-PREDICT study description states that enrollment had begun at three of more than 20 planned sites and that the retrospective international project was designed to include approximately 1,000 subjects. The protocol compares imaging features from patients who experienced myocardial infarction within 36 months of a baseline coronary CT angiography scan with clinically matched, event-free controls.

Those numbers describe the planned study and its early enrollment status, not completed findings. Until results are reported and independently evaluated, AI-PREDICT represents evidence generation rather than proof that Elucid’s software changes treatment decisions or prevents cardiovascular events.

Commercial adoption requires another set of indicators: the number and type of clinical sites using Plaque-IQ, repeat utilization, integration into established workflows, reimbursement experience and continued use beyond pilots. Elucid did not disclose customer counts, utilization data or revenue with the Series D, leaving adoption distinct from both financing and regulatory clearance.

The next gates after the financing

The most immediate milestone is an FDA determination on BioIntegrated FFR-CT. Clearance would remove a regulatory barrier to the combined platform Elucid describes, while additional agency questions or a prolonged review would preserve the present divide between the cleared plaque-analysis product and the pending physiological product.

After that come two independent tests: completed clinical evidence and measurable commercial adoption. As of September 2, the confirmed position was narrower than the funding headline alone might suggest: Elucid had secured $55 million, Plaque-IQ was cleared, and BioIntegrated FFR-CT still awaited an FDA decision.

Also read:

• Aureka Raises $100M—Its Biological Model Still Faces Clinical Proof
• MrBeast Just Hit 500 Million Subscribers — And He’s Still the Only One
• Decaf Coffee Can Still Use Methylene Chloride as FDA Reviews a Ban